Lobbying and Political Support for Vertex Pharmaceuticals Drug Access Bill
What happened
Kate Knox and Alysia Melnick of Bernstein Shur began representing Vertex Pharmaceuticals in 2024, lobbying for a bill designed to increase patient access to drugs like Journavx, a non-opioid pain medicine from Vertex. Troy Jackson, a Maine Democratic Senate hopeful, submitted testimony in favor of the bill when he served as president of the Maine Senate, citing the drug as promising and game changing. This occurred while Jackson also publicly criticized the pharmaceutical industry and high-priced lobbyists.
From freebeacon.com
Why it matters
The efforts involve Vertex Pharmaceuticals, a Boston-based drug developer that generated $12 billion in revenue in 2025, and a legislative push for expanded drug access. The lobbying efforts and political support relate directly to the market access and pricing of Vertex's specialized medications.
From freebeacon.com
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- KnoxSpeculative
Knox's firm might see increased revenue and client value due to successful lobbying efforts for Vertex Pharmaceuticals.